Pfizer (PFE) CEO Albert Bourla Receives Award

What Happened
Albert Bourla, Pfizer’s Chairman and CEO, was granted 22 units (phantom shares) on August 14, 2026 at a reported value of $26.79 per unit, totaling approximately $589. The filing lists the transaction as an award/acquisition (code A) and the reported instrument is a derivative (phantom share units), not actual common stock.

Key Details

• Transaction date: 2026-08-14; Filing date: 2026-08-17 (timely filing)
• Shares/units granted: 22 units at $26.79 each; total value ≈ $589
• Transaction type: Award/Acquisition (derivative units), not an open-market purchase
• Shares owned after transaction: Not disclosed in this Form 4
• Footnotes: F1 — each unit represents one phantom share of common stock; F2 — units were granted under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan, are cash-settled upon separation from service, and may be transferred into an alternative investment account at any time

Context
This was a compensation award of phantom (cash-settled) units rather than an outright purchase or sale of common stock; such awards are routine executive compensation and do not directly indicate a personal buy/sell market signal.